Trial Profile
A Phase 2 Safety Study of L1-79 for the Treatment of Autism
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2023
Price :
$35
*
At a glance
- Drugs Racemetirosine (Primary)
- Indications Autistic disorder
- Focus Adverse reactions
- Sponsors Yamo Pharmaceuticals
- 14 May 2018 According to a Yamo Pharmaceuticals media release, the US FDA has granted Fast Track Designation for L1-79 in autism spectrum disorder. The designation is primarily based on data from this trial.
- 12 Apr 2018 Status changed from recruiting to completed.
- 09 Nov 2016 New trial record